Hyloris Pharmaceuticals SA
XBRU:HYL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hyloris Pharmaceuticals SA
Operating Income
Hyloris Pharmaceuticals SA
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hyloris Pharmaceuticals SA
XBRU:HYL
|
Operating Income
-€7.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Ucb SA
XBRU:UCB
|
Operating Income
€2B
|
CAGR 3-Years
43%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Financiere de Tubize SA
XBRU:TUB
|
Operating Income
-€3m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hyloris Pharmaceuticals SA
Glance View
Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. The company is headquartered in Liege, Liege and currently employs 14 full-time employees. The company went IPO on 2020-06-29. Its focus is on re-engineering cardiovascular products. Additionally, it also further develops and improves already-approved pharmaceuticals and established products, creating new and different solutions. The Company’s diverse product-development portfolio spans a wide range of therapeutic indications and dosage forms.
See Also
What is Hyloris Pharmaceuticals SA's Operating Income?
Operating Income
-7.7m
EUR
Based on the financial report for Dec 31, 2025, Hyloris Pharmaceuticals SA's Operating Income amounts to -7.7m EUR.
What is Hyloris Pharmaceuticals SA's Operating Income growth rate?
Operating Income CAGR 5Y
-9%
Over the last year, the Operating Income growth was -21%. The average annual Operating Income growth rates for Hyloris Pharmaceuticals SA have been 13% over the past three years , -9% over the past five years .
